Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01685814 | Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance | unknown | Phase 3 | 406 | Wuerzburg University HospitalOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT03523468 | Curative Effect and Quality of Life Between Uniportal and Open Sleeve Lobectomy for Central Type Lung Cancer | unknown | Phase 3 | 200 | Lei JiangOTHER | 1 | Apr 25, 2023 |
| clinicaltrials |
| NCT03958890 | A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC) | unknown | Phase 3 | 489 | Shanghai Henlius BiotechINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05816668 | Tranexamic Acid's Effects in Patients Undergoing Laparoscopic Radical Prostatectomy(Transamin) | unknown | Phase 3 | 122 | Instituto do Cancer do Estado de São PauloOTHER | 0 | Apr 18, 2023 | clinicaltrials |
| NCT05817201 | Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy | unknown | Phase 2 / Phase 3 | 60 | Taizhou HospitalOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT01675219 | Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9) | unknown | Phase 3 | 400 | Turku University HospitalOTHER_GOV | 1 | Apr 13, 2023 | clinicaltrials |
| NCT04792749 | Clinical Effects of Metformin on Fertility-sparing Treatment for Early Endometrial Cancer | unknown | Phase 3 | 77 | Samsung Medical CenterOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05049707 | Does Perioperative Intravenous Magnesium Affect Postoperative Quality of Recovery in Craniotomy Surgery Patients? | unknown | Phase 3 | 110 | Thomas Jefferson UniversityOTHER | 0 | Apr 12, 2023 | clinicaltrials |
| NCT05802992 | The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients | unknown | Phase 3 | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT03391934 | Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer | unknown | Phase 3 | 234 | CinnagenINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT03991403 | Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC | unknown | Phase 3 | 228 | Samsung Medical CenterOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT05104281 | Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer | unknown | Phase 3 | 60 | Qingdao Central HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05790096 | Effectiveness and Safety Study of Filgrastine® in Patientes With Breast Cancer Treated With Myelotoxic Chemotherapy | unknown | Phase 3 | 60 | Blau Farmaceutica S.A.INDUSTRY | 0 | Mar 29, 2023 | clinicaltrials |
| NCT03700476 | Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma(CONTINUUM) | unknown | Phase 3 | 425 | Sun Yat-sen UniversityOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT00326456 | MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer | unknown | Phase 3 | 820 | National Cancer Institute, NaplesOTHER | 3 | Mar 27, 2023 | clinicaltrials |
| NCT00412022 | HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.(HOBOE) | unknown | Phase 3 | 1,294 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT00526396 | STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study(STAD-1) | unknown | Phase 3 | 160 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT00660842 | Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer(MITO-7) | unknown | Phase 3 | 800 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01405586 | MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer(MILES-3) | unknown | Phase 3 | 299 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01656551 | MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer(MILES-4) | unknown | Phase 3 | 232 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01802749 | Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer(MITO16MANGO2b) | unknown | Phase 3 | 406 | National Cancer Institute, NaplesOTHER | 5 | Mar 24, 2023 | clinicaltrials |
| NCT02633189 | Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer(BEVERLY) | unknown | Phase 3 | 200 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05351346 | Genotype-guided Treatment in DLBCL | unknown | Phase 3 | 1,100 | Ruijin HospitalOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05620355 | Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids. | unknown | Phase 3 | 312 | Bio Genuine (Shanghai) Biotech Co., Ltd.INDUSTRY | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05776940 | Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis | unknown | Phase 3 | 116 | Air Force Military Medical University, ChinaOTHER | 0 | Mar 20, 2023 | clinicaltrials |
| NCT04924699 | A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer | unknown | Phase 2 / Phase 3 | 350 | Shanghai Miracogen Inc.INDUSTRY | 1 | Mar 17, 2023 | clinicaltrials |
| NCT03846362 | A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML | unknown | Phase 3 | 500 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05408221 | the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma(HCC) | unknown | Phase 2 / Phase 3 | 576 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05753865 | A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound) | unknown | Phase 3 | 454 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05728632 | Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines(CONTROL) | unknown | Phase 3 | 80 | Giulio StefaniniOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT05739630 | M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia | unknown | Phase 2 / Phase 3 | 60 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT05111197 | Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy(TRAILOCLORI01) | unknown | Phase 3 | 112 | Institut Cancerologie de l'OuestOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04387695 | SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT | unknown | Phase 3 | 54 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02172872 | "InDACtion" vs "3+7" Induction in AML | unknown | Phase 3 | 606 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Feb 15, 2023 | clinicaltrials |
| NCT05718167 | TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. | unknown | Phase 3 | 570 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05720026 | Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer | unknown | Phase 3 | 560 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 9, 2023 | clinicaltrials |
| NCT02025036 | Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer(CRTCOESC) | unknown | Phase 3 | 249 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05244577 | Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer | unknown | Phase 3 | 75 | Shi YanxiaOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05325528 | Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases | unknown | Phase 2 / Phase 3 | 40 | Zhejiang UniversityOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT04222114 | Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis | unknown | Phase 3 | 282 | LintonPharm Co.,Ltd.INDUSTRY | 3 | Jan 31, 2023 | clinicaltrials |
| NCT02125396 | Adjuvant Radiotherapy Comparing TACE for Curative HCC(ARTC-HCC) | unknown | Phase 3 | 150 | Guangxi Medical UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT05698082 | FOS Immunohistochemical Staining of Colorectal Cancer and Its Adjacent Tissues | unknown | Phase 2 / Phase 3 | 120 | xiaoliang HuangOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT03849768 | A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients | unknown | Phase 3 | 429 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 20, 2023 | clinicaltrials |
| NCT02914158 | Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women(ASPAIT) | unknown | Phase 3 | 680 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05670054 | Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients | unknown | Phase 3 | 116 | Mansoura UniversityOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT05280444 | Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma | unknown | Phase 2 / Phase 3 | 216 | Zhongda HospitalOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05344924 | TACE Combined With Penpulimab and Anlotinib for Advanced HCC | unknown | Phase 2 / Phase 3 | 109 | Zhongda HospitalOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05661240 | Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment | unknown | Phase 2 / Phase 3 | 348 | Jiangsu Healthy Life Innovation Medical Technology Co., LtdINDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT05648071 | First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial(SPBPDC) | unknown | Phase 3 | 60 | Qianfoshan HospitalOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT05446883 | QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer | unknown | Phase 3 | 498 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 30, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Apr 27, 2023source: clinicaltrials